



## Merus to Present at Upcoming Investor Conferences

May 27, 2025

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- [Merus N.V.](#) (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences:

- William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ET
- Jefferies Global Healthcare Conference: Wednesday, June 4 at 3:10 p.m. ET

The webcasts of the presentations will be contemporaneously available on the [Investors page](#) of the Company's website. The archived presentations will also be available there for a limited time after the event.

### About Merus

[Merus](#) is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as [Multiclonics®](#). Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit [Merus' website](#), [LinkedIn](#) and [Bluesky](#).

Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.

### Investor and Media Inquiries:

Sherri Spear  
Merus N.V.  
SVP Investor Relations and Strategic Communications  
617-821-3246  
[s.spear@merus.nl](mailto:s.spear@merus.nl)

Kathleen Farren  
Merus N.V.  
Director IR/Corp Comms  
617-230-4165  
[k.farren@merus.nl](mailto:k.farren@merus.nl)

Source: Merus N.V.